Paul Spurr

USPTO Granted Patents = 17 (Patent Applications = 5)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 4)

Average Co-Inventor Count = 2.0

ph-index = 3

Forward Citations = 36(Granted Patents)

Location History:

Basel, CH (1992)
Riehen, CH (1996 - 2019)

Company Filing History:

15 out of 4,942

Hoffmann-la Roche Inc.

Basilea Pharmaceutica Ag

patents

Years Active: 1992-2025

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12221420 - Process for the preparation of substituted pyrazole derivatives (2025-02-11),

2. 10208041 - Diazabicyclooctane compounds (2019-02-19),

3. 10017749 - Mutant transaminases as well as methods and uses relating thereto (2018-07-10),

4. 9447099 - Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine (2016-09-20),

5. 8293916 - Diazole derivatives (2012-10-23),

6. 8222246 - Substituted isoxazoles (2012-07-17),

7. 7459563 - Process for the preparation of isonicotinic acid derivatives (2008-12-02),

8. 7087761 - Cyclization process for substituted benzothiazole derivatives (2006-08-08),

9. 6531597 - Process for preparation of 2-phenyl acetic acid derivatives (2003-03-11),

10. 6384214 - Process for producing cephalosporin derivatives (2002-05-07),

11. 6080866 - Process for the manufacture of 2,5-disubstituted pyridines (2000-06-27),

12. 5977381 - Process for making 3-amino-pyrolidine derivatives (1999-11-02),

13. 5902738 - Enzymatic acylation (1999-05-11),

14. 5670640 - Process for the manufacture of imidazodiazepine derivatives (1997-09-23),

15. 5578728 - Process for the preparation of a benzo(a)quinolizione derivative (1996-11-26),

Hello! I will gladly assist you in creating an article about the renowned inventor Paul Spurr.

Title: The Innovative Journey of Paul Spurr: Pioneering Antibacterial Agents and Enzyme Mutants

Introduction:

Paul Spurr, a distinguished inventor hailing from Riehen, Switzerland, has left an indelible mark in the field of pharmaceuticals with a total of 16 patents to his name. His inventive spirit and dedication have led to groundbreaking discoveries that have the potential to revolutionize the medical landscape.

Latest Patents:

Among his latest patents is the development of Diazabicyclooctane compounds. These compounds, formulated as per Formula (II) or its derivatives, exhibit promising characteristics as antibacterial agents and β-lactamase inhibitors. This innovation holds tremendous value in combating infectious diseases effectively.

Additionally, Paul Spurr's creation of mutant transaminases marks another significant milestone. These transaminases, engineered for enhanced activity over wild-type counterparts, have wide-ranging applications in amine production. His inventive solutions are poised to streamline chemical processes and drive efficiency in the pharmaceutical industry.

Career Highlights:

Throughout his illustrious career, Paul Spurr has made significant contributions to leading pharmaceutical companies. Notably, he has been associated with Hoffmann-La Roche Inc. and Roche Vitamins Inc., where his innovative prowess has been instrumental in shaping cutting-edge pharmaceutical products and technologies.

Collaborations:

In his professional journey, Paul Spurr has collaborated with esteemed individuals such as Beat Wirz and Steven Paul Hanlon. Their combined expertise and dedication have fostered a culture of innovation, resulting in groundbreaking inventions that hold immense promise for the future of medicine.

Conclusion:

Paul Spurr's exemplary work in the realm of pharmaceutical inventions underscores his unwavering commitment to advancing healthcare solutions. His patented innovations in antibacterial agents and enzyme mutants stand as a testament to his vision and ingenuity. As a visionary inventor, Paul Spurr continues to push the boundaries of scientific exploration, leaving an enduring legacy in the realm of pharmaceutical innovation.

This text is generated by artificial intelligence and may not be accurate.